Is Palivizumabe a Protective Factor for the Development of Asthma in Children? A Systematic Review With Metanalysis.

Introduction: Premature infants are at increased risk of developing chronic respiratory diseases, predisposing them to severe infections, such as those caused by respiratory syncytial virus (RSV). Palivizumab reduces the severity of RSV infections in high-risk children; however, its relationship with asthma development in premature infants remains unclear.

Objective: This systematic review with meta-analysis aimed to review the literature and assess whether prophylaxis with palivizumab protects premature infants without congenital heart disease from developing asthma.